Funding
1 min read
neuroClues closed a €10M Series A, bringing total capital to €25M, to commercialise its CE‑marked ey...
The AMW Read
The article updates the player map for Vertical AI - Healthcare/Bio with a mid-sized Series A round for a specialized diagnostic hardware/AI company.
NoveltySignificance
Healthcare & Bio · Player Map
neuroClues closed a €10M Series A, bringing total capital to €25M, to commercialise its CE‑marked eye‑tracking device that delivers AI‑derived neurological biomarkers in a 10‑minute exam. With 30+ units already deployed across seven European countries, the platform aims to cut misdiagnosis rates (currently 1 in 5) and enable earlier intervention for diseases like Parkinson's, where neuron loss can reach 65% before correct diagnosis. The funding also earmarks U.S. regulatory preparation, positioning neuroClues as a scalable, data‑driven alternative to costly imaging.
